Skip to main content
HR 3932 111th Congress House Health Drug safety, medical device, and laboratory regulation

Strengthening of FDA Integrity Act of 2009

Introduced: October 27, 2009 See on congress.gov
Sign in to write a letter Sign in to watch
 Everywhere this bill has been 3 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Oct 28, 2009
Referred to the Subcommittee on Health.
Oct 27, 2009
Introduced in House
Oct 27, 2009
Referred to the House Committee on Energy and Commerce.
 Plain-English summary Congressional Research Service

Strengthening of FDA Integrity Act of 2009 - Amends the Federal Food, Drug, and Cosmetic Act to apply debarment provisions currently applicable to abbreviated new drugs to any drug products, including new drugs, animal drugs, exported drugs, biological products, and medical devices.

Expands the conditions under which persons (i.e., partnerships, corporations, and associations) are subject to mandatory and permissive debarment preventing such persons from submitting an application for approval of a drug product.

Requires the Secretary of Health and Human Services (HHS), in determining the appropriateness and the period of debarment, to consider whether debarment will affect the public health because sufficient quantities of the drug would not be available.

Requires the Secretary to annually report to Congress on the implementation of debarment provisions.

What's happening now October 28, 2009

Referred to the Subcommittee on Health.

 Committees of jurisdiction 2
 Cosponsors 1
All 1 Republican 1